PRESS RELEASE published on 12/09/2025 at 07:30, 7 months 1 day ago OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation OSE Immunotherapeutics unveils 2026–2028 strategic plan focusing on Tedopi's phase 3, rare indications for Lusvertikimab, subcutaneous formulation in UC, and maintaining scientific leadership Strategic Plan Scientific Leadership OSE Immunotherapeutics Tedopi Phase 3 Lusvertikimab Indications
PRESS RELEASE published on 10/16/2025 at 19:58, 8 months 25 days ago RAPPORT FINANCIER SEMESTRIEL 2025
BRIEF published on 10/15/2025 at 19:05, 8 months 26 days ago OSE Immunotherapeutics publie ses résultats financiers du premier semestre 2025 Baisse Des Revenus OSE Immunotherapeutics Dépenses De R&D Piste De Trésorerie Résultats Financiers 2025
BRIEF published on 10/15/2025 at 19:05, 8 months 26 days ago OSE Immunotherapeutics Reports 2025 First Half Financial Results Revenue Decline OSE Immunotherapeutics Cash Runway R&D Expenses 2025 Financial Results
PRESS RELEASE published on 10/15/2025 at 19:00, 8 months 26 days ago OSE Immunotherapeutics Reports First Half 2025 Financial Results OSE Immunotherapeutics reports first half 2025 financial results with operating loss of 15.8 million euros and net loss of 15.1 million euros. Research and development expenses increased 6.7% Financial Results Net Loss Operating Loss OSE Immunotherapeutics Research And Development Expenses
PRESS RELEASE published on 10/15/2025 at 19:00, 8 months 26 days ago OSE Immunotherapeutics publie ses résultats financiers du 1er semestre 2025 OSE Immunotherapeutics publie ses résultats financiers du 1er semestre 2025, montrant une perte nette de 15,1 millions d'euros. Les activités sont estimées financées jusqu'au 4ème trimestre 2026 Résultats Financiers Biotechnologie Perte Nette OSE Immunotherapeutics Horizon De Trésorerie
BRIEF published on 10/09/2025 at 16:02, 9 months 1 day ago OSE Immunotherapeutics : Fin d'une action de concert entre actionnaires Actionnaires Franchissement De Seuil Capital Et Droits De Vote OSE Immunotherapeutics Pacte Résilié
BRIEF published on 10/09/2025 at 16:02, 9 months 1 day ago OSE Immunotherapeutics: End of a concerted action between shareholders Shareholders Threshold Crossing OSE Immunotherapeutics Capital And Voting Rights Terminated Agreement
PRESS RELEASE published on 10/09/2025 at 15:57, 9 months 1 day ago Franchissement de seuils Fin de convention et action de concert chez OSE Immunotherapeutics suite à franchissement de seuils de M. Emile Loria, Mme Dominique Costantini, M. Alexis Peyroles, MS Medical Synergy SA et Aperana Consulting SARL OSE Immunotherapeutics Franchissement Seuils Fin Convention Action Concert Emile Loria
BRIEF published on 09/30/2025 at 19:35, 9 months 10 days ago OSE Immunotherapeutics: Reorganization of the Board of Directors Board Of Directors Biotechnology Immunotherapy OSE Immunotherapeutics Markus Cappel
Published on 07/11/2026 at 02:50, 3 hours 17 minutes ago Alaska Energy Metals Reports on At-the-Market Equity Financing Program
Published on 07/11/2026 at 02:00, 4 hours 7 minutes ago Battery X Metals Presents Positive Preliminary Lithium-Ion Battery Rebalancing Trial Results Demonstrating Significant Estimated Driving Range Improvements and Accelerated Commercialization Progress of its Patent-Pending Lithium-Ion Battery Rebalancing Te
Published on 07/11/2026 at 02:00, 4 hours 7 minutes ago Discovery Energy Metals Announces Non-Brokered Private Placement Financing
Published on 07/11/2026 at 00:00, 6 hours 7 minutes ago Onco-Innovations Completes Analytical Reference Standard Preparation Program for ONC010’s API
Published on 07/11/2026 at 04:00, 2 hours 7 minutes ago CUHK Achieves Top 20 Global Ranking in QS World University Rankings 2027
Published on 07/11/2026 at 04:00, 2 hours 7 minutes ago L’Université chinoise de Hong Kong (CUHK) se classe parmi les 20 meilleures universités mondiales dans le classement mondial des universités 2027 de Quacquarelli Symonds (QS)
Published on 07/10/2026 at 18:40, 11 hours 27 minutes ago AFX Surpasses $1.1 Billion in Total Trading Volume, Highlighting Capital Efficiency in On-Chain Derivatives
Published on 07/10/2026 at 17:45, 12 hours 22 minutes ago WYF Launches Global AI Talent Compact at AI for Good Global Summit 2026
Published on 07/10/2026 at 18:00, 12 hours 7 minutes ago Half-year liquidity contract statement for CEGEDIM
Published on 07/10/2026 at 18:00, 12 hours 7 minutes ago Bilan semestriel du contrat de liquidité de la société CEGEDIM
Published on 07/10/2026 at 17:45, 12 hours 22 minutes ago Bilan semestriel de mise en œuvre du contrat de liquidité
